Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
May 10, 2022 16:05 ET
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic...
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
May 04, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 02, 2022 16:35 ET
|
Sana Biotechnology, Inc
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts...
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
March 16, 2022 08:30 ET
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end cash position of...
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 09, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
March 08, 2022 16:35 ET
|
Sana Biotechnology, Inc
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data...
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
January 11, 2022 06:00 ET
|
Sana Biotechnology, Inc
License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies ...
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
January 10, 2022 16:30 ET
|
Sana Biotechnology, Inc
SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
December 12, 2021 09:05 ET
|
Sana Biotechnology, Inc
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...